References
- Abdul Rahman SA, Loutfi K, Turk T, et al. A challenging case of ALK-negative anaplastic large cell lymphoma in a 12-year-old boy: a rare case report from Syria. Ann Med Surg. 2022;79:104085.
- Wang HY, Thorson JA, Hinds BR, et al. Cutaneous intralymphatic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma arising in a patient with multiple rounds of breast implants. J Cutan Pathol. 2021;48(5):659–662.
- Zhang Y, Chen M, Yu Y, et al. Primary cutaneous anaplastic large-cell lymphoma with DUSP22-IRF4 rearrangement following insect bites. J Cutan Pathol. 2022;49(2):187–190. doi:10.1111/cup.14147
- Abe H, Nakamura T, Yoshitomi M, et al. The usefulness of straight chemotherapy for dermal exposed anaplastic lymphoma kinase fusion-positive anaplastic large-cell lymphoma with intracranial invasion. Asian J Neurosurg. 2019;14(4):1218–1221. doi:10.4103/ajns.AJNS_158_19
- Donato EM, Fernández-Zarzoso M, Hueso JA, et al. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018;11:4583–4590. doi:10.2147/OTT.S141053
- Koh Y. Extended use of brentuximab vedotin before autologous stem-cell transplantation would benefit refractory systemic anaplastic large-cell lymphoma. Clin Case Rep. 2018;6(5):798–801. doi:10.1002/ccr3.1461